Press release
Liqomics Launches LymphoVista: Breakthrough in Minimal Residual Disease (MRD) Monitoring and Genotyping for Lymphoma Patients
Liqomics is proud to announce the launch of LymphoVista
LymphoVista (https://liqomics.com/detect-lymphoma-lymphovista/) is an advanced ctDNA-based assay specifically designed for minimal residual disease (MRD) monitoring and genotyping in lymphoma patients. LymphoVista leverages high-sensitivity circulating tumor DNA (ctDNA) detection, setting a new standard in MRD testing across lymphomas including Hodgkin Lymphoma, Diffuse Large B-Cell Lymphoma (DLBCL), Central Nervous System (CNS) Lymphomas and Follicular Lymphoma.
Revolutionizing MRD Testing in Hodgkin Lymphoma and Other Lymphomas
LymphoVista addresses a critical need in genotyping and monitoring of MRD in lymphoma, providing a level of sensitivity, specificity, and accuracy that has been lacking in many current MRD assays. "Many existing cfDNA assays fail to meet the precision needed for lymphoma-specific MRD monitoring," said Sven Borchmann MD/PhD, founder and managing director of Liqomics. "With LymphoVista, we introduce a validated assay that can monitor MRD with accuracy as low as a few molecules of ctDNA per million enabling clinicians to make more data-driven treatment decisions."
LymphoVista HL Validation: High Sensitivity and Specificity
Validation studies confirm LymphoVista as a high-precision tool for MRD assessment. Key validation metrics include:
- Sensitivity > 91% and Specificity > 99.99% for variant detection (genotyping) allowing reliable identification of SNPs and InDels
- Limit of Detection (LoD) for MRD: 0.000654%, making it highly suitable for detecting minimal disease presence.
Clinical Validation Demonstrates Prognostic Power in Hodgkin Lymphoma
A clinical validation study for LymphoVista was performed in Hodgkin lymphoma (HL) involving 72 patients. This study demonstrated that MRD detection following two cycles of therapy effectively stratified patients based on risk. Patients MRD-negative patients after two cycles of chemotherapy had a 4-year progression-free survival (PFS) of 95.3% (95%-CI: 88.7 100) while patients who were MRD-positive after two cycles of chemotherapy had a 4-year PFS of 72.2% (95%-CI: 41.5-100) resulting in a hazard ratio of 6.9 (95%-CI: 4.5-10.6). In conclusion, MRD-negative patients showed very good outcomes, while MRD-positive patients had a significantly higher risk of relapse. This clinical performance study shows LymphoVista is a valuable tool for MRD detection in lymphoma, particularly Hodgkin lymphoma.
LymphoVista HL: Setting a New Benchmark for MRD-Guided Clinical Trials in Lymphoma
The launch of LymphoVista heralds a new era in personalized medicine for lymphoma, laying a foundation for MRD-guided clinical trials. The assay's validated accuracy and sensitivity support its use in clinical trials and can inform treatment decisions based on real-time MRD results.
For more information on LymphoVista or collaboration opportunities with Liqomics, please contact: https://liqomics.com/contact/
About Liqomics
Liqomics is a pioneering molecular diagnostics company focused on developing cutting-edge circulating tumor DNA (ctDNA) and cell-free DNA (cfDNA) assays to advance personalized medicine in oncology, with a strong emphasis on minimal residual disease (MRD) detection and genotyping in lymphomas and other hematological malignancies. Liqomics uses state-of-the-art technology for its assays which are rigorously validated to create highly sensitive diagnostic tools that enable precise disease monitoring and optimized treatment decisions.
The company is headquartered in Cologne, Germany. Liqomics' mission is to empower clinicians and patients with data-driven insights through validated cfDNA-based assays, ensuring that patients receive timely and effective care. Through its dedication to innovation and precision, Liqomics aims to set new standards in MRD monitoring and genotyping, enabling clinicians to make real-time adjustments in treatment plans based on the genetic profile and MRD status of each patient.
Media Contact
Company Name: Liqomics GmbH
Contact Person: Sven Borchmann MD/PhD Managing Director
Email: Send Email [http://www.universalpressrelease.com/?pr=liqomics-launches-lymphovista-breakthrough-in-minimal-residual-disease-mrd-monitoring-and-genotyping-for-lymphoma-patients]
Phone: (+49) 221 69 056 597
Address:Hermulheimer Str. 68
City: Koln 50969
Country: Germany
Website: https://liqomics.com/
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Liqomics Launches LymphoVista: Breakthrough in Minimal Residual Disease (MRD) Monitoring and Genotyping for Lymphoma Patients here
News-ID: 3740427 • Views: …
More Releases from Getnews
Spectrum Electric Redefines What It Means to Be a Full-Service Electrical Partne …
Image: https://www.globalnewslines.com/uploads/2025/12/f1b1018646e29745b0c22c200a9eee9e.jpg
Spectrum Electric, a Central Florida-based electrical contractor led by CEO Richard Forthman, is gaining regional attention for its proactive, client-focused approach to electrical service and commercial construction.
With more than 15 years in business and significant growth under Forthman's leadership over the past eight years, Spectrum Electric has positioned itself as an up-and-coming regional leader in the electrical contracting industry. While the company maintains a strong residential and service footprint…
The U.S. Green Card: Turning a Temporary Stay into a Permanent American Future
Image: https://www.globalnewslines.com/uploads/2025/12/1766183100.jpg
For many people, a U.S. visa is only the beginning. What they truly want is certainty - the ability to live, work, and plan their future in the United States without expiry dates, renewals, or ongoing fear that a single decision could unravel years of effort.
That certainty is called a Green Card.
Yet despite its importance, the Green Card [https://larhdellaw.com/] process is often misunderstood. Some believe it is only for…
The L-1 Visa: How Global Businesses Expand to the U.S. Without Starting From Scr …
Image: https://www.globalnewslines.com/uploads/2025/12/1766182907.jpg
For international companies with ambitions to enter the United States, few visa options are as powerful - or as misunderstood - as the L-1 Intracompany Transfer Visa.
When used correctly, the L-1 visa allows established businesses to expand into the U.S. market, transfer trusted senior staff, and build a long-term American presence without relying on lotteries, third-party sponsors, or speculative investment routes. When used incorrectly, it becomes one of the…
The B-1/B-2 Visitor Visa: Why Careful Preparation Matters More Than Ever
Image: https://www.globalnewslines.com/uploads/2025/12/1766182346.jpg
The B-1/B-2 visitor visa [https://larhdellaw.com/]is often described as the most common U.S. visa. That description, while true, can be misleading. Its familiarity causes many applicants to underestimate how closely these visas are scrutinised - and how easily an application can be refused.
In today's immigration environment, visitor visas are assessed with a level of caution that surprises even experienced international travellers. The rules themselves have not dramatically changed, but how…
More Releases for MRD
Minimal Residual Disease (MRD) Testing Market Demand in 2034
Rising adoption of next-generation sequencing (NGS), expanded use of MRD in hematologic malignancies, and growing integration of liquid biopsy technologies are propelling strong global market growth.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/50110
Introduction
The Minimal Residual Disease (MRD) Testing Market is expanding rapidly as oncologists and diagnostic laboratories increasingly rely on highly sensitive molecular tests to detect trace levels of cancer cells that persist after treatment. MRD testing-using flow…
Lucintel Forecasts the Global MRD Testing Market to Reach $3.4 billion by 2031
According to a market report by Lucintel, the future of the global MRD testing market looks promising with opportunities in the hospitals and specialty clinic, diagnostic laboratory, and academic & research institutes markets. The global MRD testing market is expected to reach an estimated $3.4 billion by 2031 from $1.6 billion in 2024, at a CAGR of 11.7% from 2025 to 2031. The major drivers for this market are increasing…
MRD Testing Market Report: Trends, Forecast and Competitive Analysis to 2031
The future of the global MRD testing market looks promising with opportunities in the hospitals and specialty clinic, diagnostic laboratory, and academic & research institutes markets. The global MRD testing market is expected to reach an estimated $3.4 billion by 2031 with a CAGR of 11.7% from 2025 to 2031. The major drivers for this market are increasing occurrence of blood-related cancers, growing global elderly population, and progress in technology…
Lucintel Forecasts the Global MRD Testing Market to Reach $3.4 billion by 2031
According to a market report by Lucintel, the future of the global MRD testing market looks promising with opportunities in the hospitals and specialty clinic, diagnostic laboratory, and academic & research institutes markets. The global MRD testing market is expected to reach an estimated $3.4 billion by 2031 from $1.6 billion in 2024, at a CAGR of 11.7% from 2025 to 2031. The major drivers for this market are increasing…
Lucintel Forecasts the Global MRD Testing Market to Reach $3.4 billion by 2031
According to a market report by Lucintel, the future of the global MRD testing market looks promising with opportunities in the hospitals and specialty clinic, diagnostic laboratory, and academic & research institutes markets. The global MRD testing market is expected to reach an estimated $3.4 billion by 2031 from $1.6 billion in 2024, at a CAGR of 11.7% from 2025 to 2031.
According to a market report by Lucintel, the future…
Global MRD Testing Market Set to Reach USD 3.72 Billion by 2030
➤ Global Minimal Residual Disease (MRD) Testing Market to Reach USD 3.72 Billion by 2030, Driven by Technological Advancements and Rising Cancer Incidence
The global Minimal Residual Disease (MRD) Testing Market is projected to expand from USD 1.60 billion in 2023 to USD 3.72 billion by 2030, registering a robust Compound Annual Growth Rate (CAGR) of 12.8% during the forecast period.
➤ Competitive Landscape and Regional Demand
The MRD testing market…
